共 101 条
[1]
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin. 71 209-249
[2]
Ferlay J(2016)Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol Off J Eur Soc Med Oncol. 27 v38-v49
[3]
Siegel RL(2005)ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer Ann Oncol Off J Eur Soc Med Oncol. 16 i22-i23
[4]
Smyth EC(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med. 355 11-20
[5]
Verheij M(2011)Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial J Clin Oncol Off J Am Soc Clin Oncol. 29 1715-1721
[6]
Allum W(2019)Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra Lancet (London, England). 393 1948-1957
[7]
Cunningham D(2009)A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma Br J Cancer. 100 1725-1730
[8]
Cervantes A(2007)Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial Ann Oncol Off J Eur Soc Med Oncol. 18 1673-1679
[9]
Arnold D(2015)NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors Int J cancer. 137 678-685
[10]
Cunningham D(2010)Frailty as a predictor of surgical outcomes in older patients J Am Coll Surg. 210 901-908